Posts

statin use after breast cancer dec mortality

  a recent article found that in patients with early breast cancer, statin use after the diagnosis of breast cancer was associated with lower all-cause and breast cancer-specific mortality particularly among patients with hormone receptor-positive subtypes: see breast cancer statin use helps JAMAonc2026 in dropbox, or doi:10.1001/jamanetworkopen.2026.16375 Details : -- 7389 female patients with early invasive breast cancer (BC) in Finland were included in this retrospective population-based cohort study,  based on the Finnish national registries from 1995 and 2013     -- 2313 who were on statins after their BC diagnosis and outcomes were compared to 5076 who were not on statins -- patient characteristics, comparing the groups with breast cancer diagnosis who were on statins after BC diagnosis vs those women having no statins after BC diagnosis:     -- median age: 64 vs 58 yo     -- median follow-up time: 7.4 vs 6.0 years     -- deaths: ...
Post a Comment
Read more

new lipoprotein(a) inhibitor pelacarsen was withdrawn after trial

as a reference to the Lp(a) studies in the pipeline, one of which involved direct PCSK9 effects: enclisiran (which is also spelled inclisiran in the NJM study...), which the FDA unexpectedly (by me) approved without documentation of clinical benefit: https://gmodestmedblogs.blogspot.com/2025/11/oral-pcsk9-improves-all-bad-lipids.html  - -- as a summary of what I have found of several of these Lp(a) inhibitors:     -- muvalapin (oral small-molecule): 63-65% reduction in Lp(a), with benefit within 4 weeks: https://jamanetwork.com/journals/jama/fullarticle/2808864       -- pelacarsen (antisense oligonucleotide that targets the Lp(a) gene): up to 80% reduction in Lp(a):   https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- evinacumab (anti-ANGPTL3 mAb): 16.5% reduction in Lp(a): https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- lomitapide (microsomal triglyceride transf...
Post a Comment
Read more

are GLP1's associated with pancreatitis??

Image
  A recent study found that GLP-1 receptor agonists were not associated with more acute pancreatitis than sulfonylureas. There was a small increase in GLP-1 related pancreatitis that was offset by decreased alcohol- and triglyceride-related pancreatitis attributable to the GLP-1s: see GLP-1 pancreatitisBMJ2026 in dropbox, or doi:10.1136/ bmjmed-2025-002183 Details : -- 333,687 patients were studied who had type 2 diabetes and antidiabetic therapy was initiated by a GLP-1 receptor agonist (n=132,551) or a sulfonylurea (n= 201,136), between January 2017 and January 2024, from the Veterans Affairs healthcare system databases -- mean age 66, 75% white/21% black -- smoking: never 43%/former 38%/current 20%; alcohol use disorder 6% -- area deprivation index 57 (a composite of socioeconomic disadvantage based on education, income, employment, and other poverty measures, measured at the participants' location, with values ranging from low to high of 0 to 100) -- BMI 34, A1c 8.6%, eGFR 76 -...
Post a Comment
Read more